<p>OraSure Technologies, Inc. (NASDAQ:OSUR - 获取免费报告) 的股价在周二的交易中突破了其 200 日移动平均线。该股票的 200 日移动平均价为 2.82 美元，最高交易价达到 3.01 美元。OraSure Technologies 的股票最后交易价为 2.86 美元，成交量为 506,349 股。</p>
<p>获取 <strong>OraSure Technologies</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>OSUR 已成为几份研究分析师报告的主题。Stephens 在 11 月 12 日的研究报告中将 OraSure Technologies 的目标价从 3.50 美元下调至 3.00 美元，并对该股票给予 “持平” 评级。Weiss Ratings 在 1 月 22 日的报告中重新发布了对 OraSure Technologies 的 “卖出 (d)” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “减持”，共识目标价为 3.00 美元。</p>
<p><strong>查看我们最新的 OSUR 股票报告</strong></p>
<h2>OraSure Technologies 股价下跌 2.1%</h2>
<p>该股票的市值为 2.0515 亿美元，市盈率为-3.58，贝塔值为 0.87。该公司的 50 日移动平均价格为 2.55 美元，200 日移动平均价格为 2.82 美元。</p>
<p>OraSure Technologies (NASDAQ:OSUR - 获取免费报告) 最近在 11 月 5 日公布了其财报。这家医疗仪器供应商报告季度每股收益为 (-0.13) 美元，超出分析师一致预期的 (-0.16) 美元，超出幅度为 0.03 美元。OraSure Technologies 的净利润率为-47.92%，股本回报率为-13.61%。该业务在本季度的收入为 2709 万美元，而分析师预期为 2896 万美元。平均而言，卖方分析师预计 OraSure Technologies, Inc.在当前年度的每股收益为-0.08 美元。</p>
<h2>对 OraSure Technologies 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了 OSUR 的股票。Farther Finance Advisors LLC 在第二季度购买了 OraSure Technologies 的新股份，价值约 26,000 美元。Prudential Financial Inc.在第二季度购买了 OraSure Technologies 的新头寸，价值约 31,000 美元。Nierenberg Investment Management Company Inc.在第二季度购买了 OraSure Technologies 的新头寸，价值约 35,000 美元。L2 Asset Management LLC 在第二季度购买了 OraSure Technologies 的新股份，价值约 39,000 美元。最后，Coldstream Capital Management Inc.在第二季度将其在 OraSure Technologies 的持股增加了 128.2%。Coldstream Capital Management Inc.现在拥有 13,308 股该医疗仪器供应商的股票，价值 40,000 美元，此前在上个季度又收购了 7,477 股。目前 93.50% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>OraSure Technologies 公司简介</h2>
<p>(获取免费报告)</p>
<p>OraSure Technologies, Inc.是一家位于宾夕法尼亚州贝塞勒姆的诊断和医疗设备公司，专注于开发、制造和商业化即时检测和自我检测产品。成立于 1988 年，OraSure 建立了一系列口腔液体和其他非侵入性样本采集技术，以支持传染病、药物滥用以及健康和保健生物标志物的检测。</p>
<p>该公司的旗舰产品 OraQuick®快速 HIV 测试是首个获得美国食品和药物管理局批准的非处方口腔液体 HIV-1/2 抗体检测。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 OraSure Technologies 更好</li>
<li>你的银行账户不再安全</li>
<li>Ray Dalio 说买黄金。我说每月从中获利</li>
<li>每天一次 1 小时</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>他们刚刚试图杀死黄金</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 OraSure Technologies 吗？</h2>
<p>在考虑 OraSure Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 OraSure Technologies 并不在名单上。</p>
<p>虽然 OraSure Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奥瑞许科技

<p>OraSure Technologies（纳斯达克代码：OSUR）股票突破了其 200 日移动平均线 2.82 美元，最高交易价达到 3.01 美元，最终收于 2.86 美元。分析师设定的共识目标价为 3.00 美元，评级包括两个持有和一个卖出。该公司报告的季度每股收益为（0.13 美元），超出预期，但净利润率为负的 47.92%。机构投资者持有 93.50% 的股份。OraSure 专注于诊断和医疗设备，特别是 OraQuick®快速 HIV 检测</p>

<p>OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.82 and traded as high as $3.01. OraSure Technologies shares last traded at $2.86, with a volume of 506,349 shares changing hands.</p>
<div class="lb-trans"><p>OraSure Technologies, Inc. (NASDAQ:OSUR - 获取免费报告) 的股价在周二的交易中突破了其 200 日移动平均线。该股票的 200 日移动平均价为 2.82 美元，最高交易价达到 3.01 美元。OraSure Technologies 的股票最后交易价为 2.86 美元，成交量为 506,349 股。</p>
</div><p>Get <strong>OraSure Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>OraSure Technologies</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>OSUR has been the topic of several research analyst reports. Stephens lowered their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Reduce&#34; and a consensus target price of $3.00.</p>
<div class="lb-trans"><p>OSUR 已成为几份研究分析师报告的主题。Stephens 在 11 月 12 日的研究报告中将 OraSure Technologies 的目标价从 3.50 美元下调至 3.00 美元，并对该股票给予 “持平” 评级。Weiss Ratings 在 1 月 22 日的报告中重新发布了对 OraSure Technologies 的 “卖出 (d)” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “减持”，共识目标价为 3.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on OSUR</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 OSUR 股票报告</strong></p>
</div><h2>OraSure Technologies Trading Down 2.1%</h2>
<div class="lb-trans"><h2>OraSure Technologies 股价下跌 2.1%</h2>
</div><p>The stock has a market cap of $205.15 million, a P/E ratio of -3.58 and a beta of 0.87. The company's 50 day moving average price is $2.55 and its two-hundred day moving average price is $2.82.</p>
<div class="lb-trans"><p>该股票的市值为 2.0515 亿美元，市盈率为-3.58，贝塔值为 0.87。该公司的 50 日移动平均价格为 2.55 美元，200 日移动平均价格为 2.82 美元。</p>
</div><p>OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. OraSure Technologies had a negative net margin of 47.92% and a negative return on equity of 13.61%. The business had revenue of $27.09 million during the quarter, compared to analysts' expectations of $28.96 million. On average, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.</p>
<div class="lb-trans"><p>OraSure Technologies (NASDAQ:OSUR - 获取免费报告) 最近在 11 月 5 日公布了其财报。这家医疗仪器供应商报告季度每股收益为 (-0.13) 美元，超出分析师一致预期的 (-0.16) 美元，超出幅度为 0.03 美元。OraSure Technologies 的净利润率为-47.92%，股本回报率为-13.61%。该业务在本季度的收入为 2709 万美元，而分析师预期为 2896 万美元。平均而言，卖方分析师预计 OraSure Technologies, Inc.在当前年度的每股收益为-0.08 美元。</p>
</div><h2>Hedge Funds Weigh In On OraSure Technologies</h2>
<div class="lb-trans"><h2>对 OraSure Technologies 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of OSUR. Farther Finance Advisors LLC purchased a new stake in OraSure Technologies in the second quarter worth about $26,000. Prudential Financial Inc. purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $31,000. Nierenberg Investment Management Company Inc. bought a new position in shares of OraSure Technologies during the 2nd quarter valued at approximately $35,000. L2 Asset Management LLC purchased a new stake in OraSure Technologies in the 2nd quarter worth approximately $39,000. Finally, Coldstream Capital Management Inc. increased its holdings in OraSure Technologies by 128.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 7,477 shares in the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了 OSUR 的股票。Farther Finance Advisors LLC 在第二季度购买了 OraSure Technologies 的新股份，价值约 26,000 美元。Prudential Financial Inc.在第二季度购买了 OraSure Technologies 的新头寸，价值约 31,000 美元。Nierenberg Investment Management Company Inc.在第二季度购买了 OraSure Technologies 的新头寸，价值约 35,000 美元。L2 Asset Management LLC 在第二季度购买了 OraSure Technologies 的新股份，价值约 39,000 美元。最后，Coldstream Capital Management Inc.在第二季度将其在 OraSure Technologies 的持股增加了 128.2%。Coldstream Capital Management Inc.现在拥有 13,308 股该医疗仪器供应商的股票，价值 40,000 美元，此前在上个季度又收购了 7,477 股。目前 93.50% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>OraSure Technologies Company Profile</h2>
<div class="lb-trans"><h2>OraSure Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.</p>
<div class="lb-trans"><p>OraSure Technologies, Inc.是一家位于宾夕法尼亚州贝塞勒姆的诊断和医疗设备公司，专注于开发、制造和商业化即时检测和自我检测产品。成立于 1988 年，OraSure 建立了一系列口腔液体和其他非侵入性样本采集技术，以支持传染病、药物滥用以及健康和保健生物标志物的检测。</p>
</div><p>The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.</p>
<div class="lb-trans"><p>该公司的旗舰产品 OraQuick®快速 HIV 测试是首个获得美国食品和药物管理局批准的非处方口腔液体 HIV-1/2 抗体检测。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than OraSure Technologies</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>1 Hour Once A Day</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>They just tried to kill gold</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 OraSure Technologies 更好</li>
<li>你的银行账户不再安全</li>
<li>Ray Dalio 说买黄金。我说每月从中获利</li>
<li>每天一次 1 小时</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>他们刚刚试图杀死黄金</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OraSure Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 OraSure Technologies 吗？</h2>
</div><p>Before you consider OraSure Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 OraSure Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 OraSure Technologies 并不在名单上。</p>
</div><p>While OraSure Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OraSure Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

奥瑞许科技（NASDAQ:OSUR）的股价突破了 200 日移动平均线 - 接下来会如何发展？